Shareholders to Vote on 8 Million Share Increase for Incentive Plan, Executive Compensation Details Disclosed
MD sits 76% above its 52-week low of $11.84.
Summary
Pediatrix Medical Group filed its definitive proxy statement, proposing to increase the share pool for its incentive compensation plan by 8 million shares, which could lead to significant future dilution. The filing also details executive compensation, including high bonuses and equity awards following strong 2025 financial performance.
Key Events · Corporate Governance and Compliance · MD
-
Proposed Incentive Plan Expansion
Shareholders will vote on increasing the share pool for the 2008 Incentive Compensation Plan by 8,000,000 shares, potentially diluting existing shareholders by approximately 9.63%.
-
Executive Compensation Details
The filing discloses 2025 executive compensation, including CEO Mark S. Ordan's total compensation of $14.14 million and bonuses paid at 180% of target, reflecting strong financial performance.
-
CEO Pay Ratio
The CEO's total compensation was approximately 91 times that of the median employee in 2025.
-
Strong 2025 Financial Performance
The company reported a significant financial turnaround in 2025, with Adjusted EBITDA reaching $275.6 million, up from $224.0 million in 2024.
Analysis · MD · Industrial Applications And Services
The definitive proxy statement outlines key proposals for the upcoming annual meeting, most notably a request to increase the share reserve for the 2008 Incentive Compensation Plan by 8,000,000 shares. If approved, this represents a potential dilution of approximately 9.63% of the current outstanding shares, which is a significant amount for shareholders. The filing also details executive compensation for 2025, showing substantial bonuses paid at 180% of target and significant equity awards, including one-time "equity transformation awards" for the CEO and Chief Investment and Strategy Officer. These compensation levels reflect the company's strong financial turnaround in 2025, with Adjusted EBITDA increasing to $275.6 million. Investors should monitor the outcome of the shareholder vote on the incentive plan due to its dilutive potential.
At the time of this filing, MD was trading at $20.79 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $11.84 to $24.99. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.